Publications

Publications (selected from last 5 years):

  1. Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J, and Lotan T (2018). Clinical implications of loss of the PTEN tumor suppressor gene in prostate cancer. Nat Rev Urol, NRU-17-034VIC (in press 2018).
  2. Koti M, Xu AS, Ren KYM, Visram K, Ren R, Berman D, and Siemens DR (2017) Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. Bladder Cancer, 3:259-267. doi:10.3233/BLC-170120. online
  3. Patel PG, Selvarajah S, Guerard KP, Bartlett JMS, Lapointe J, Berman DM, Okello JBA, and Park PC (2017) Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores. PLoS One, 12:e0179732. doi:10.1371/journal.pone.0179732. online
  4. Patel P, Selvarajah S, Boursalie S, How, NE, Ejdelman J, Guerard, K-P, Bartlett JM, Lapointe J, Park PC, Okello JBA, and Berman DM (2016) Preparation of formalin-fixed paraffin embedded tissue cores for both RNA and DNA extraction. J Vis Exp, 114:e54299. doi:10.3791/54299 online
  5. Izard JP, Siemens DR, Mackillop WJ, Wei X, Leveridge MJ, Berman DM, Peng Y, and Booth CM (2015) Outcomes of squamous histology in bladder cancer: a population-based study. Urol Oncol, 33:425.e7-13. doi:10.1016/j.urolonc.2015.06.011. online
  6. Siemens DR, Mackillop WJ, Peng Y, Wei X, Berman D, and Booth CM (2015) Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: a population-based study. Urol Oncol, 33:425.e15-23 (2015). doi:10.1016/j.urolonc.2015.06.005. online
  7. Baras AS, Gandhi N, Munari E, Faraj S, Schultz L, Marchionni L, Schoenberg M, Hahn N, Hoque M, Berman D, Bivalacqua TJ, and Netto G (2015) Identification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma. PLoS One, 10:e0131245. online. doi:10.1371/journal.pone.0131245. Correction 2015 Nov 24. doi:10.1371/journal.pone.0143990.
  8. Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu J-J, Kates M, Hoque MO, Berman D, Hahn NM, Eisenberger M, Netto GJ, Schoenberg MP, and Bivalacqua TJ (2015) Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: predicting response and assessing outcomes. Urol Oncol, 33:204.e1-7. doi:10.1016/j.urolonc.2015.02.011 online
  9. Booth CM, Siemens DR, Wei XJ, Peng Y, Berman DM, and Mackillop WJ (2015) Pathologic factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer. BJU Int, 116:373-381. doi:10.1111/bju.12913. online
  10. Carvalho FL, Marchionni L, Gupta A, Kummangal BA, Schaeffer EM, Ross AE, and Berman DM (2015) HES6 promotes prostate cancer aggressiveness independently of Notch signalling. J Cell Mol Med, 19:1624-1636. doi:10.1111/jcmm.12537. online
  11. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Chouieri TK, Loda M, Stack E, and Rosenberg J (2015) HER2 as a target in invasive urothelial carcinoma. Cancer Med, 4:844-852. Doi: 10.1002/cam4.432. online
  12. Leveridge MJ, Siemens DR, Mackillop WJ, Peng Y, Tannock IF, Berman DM, and Booth CM (2015) Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology, 85:791-798. Doi:10.1016/j.urology.2014.12.027. online
  13. Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, Booth CM (2014) Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. Int J Urol, 22:163-170. doi:10.1111/iju.12611. Online
  14. Wang DH, Tiwari A, Kim ME, Clemons NJ, Regmi NL, Hodges WA, Berman DM, Montgomery EA, Watkins DN, Zhang X, Zhang Q, Jie C, Spechler SJ, Souza RF (2014) Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett’s metaplasia. J Clin Invest, 124: 3767-3780. doi:10.1172/JCI66603. Online
  15. Booth CM, Siemens DR, Wei X, Peng Y, Berman DM, Mackillop WJ (2014) Pathologic factors associated with survival benefit from adjuvant chemotherapy: a population-based study of bladder cancer. BJU Int, 116:373-381. doi:10.1111/bju.12913. Online
  16. Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O’Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE (2014) Identification of ALK gene alterations in urothelial carcinoma. PLoS One 9:e103325. doi:10.1371/journal.pone.0103325. Online
  17. Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P (2014) Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Sci, 12:40. doi:10.1186/1477-5956-12-40. Online
  18. Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P (2014) Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer, 111: 1201-1212. doi:10.1038/bjc.2014.396. Online
  19. Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM (2014) PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol, 28:128-137. doi:10.1038/modpathol.2014.85. Online
  20. Carvalho FLF, Simons BW, Eberhart CG and Berman DM (2014), Notch signaling in prostate cancer: A moving target. Prostate, 74:933-945. doi:10.1002/pros.22811. Online
  21. Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, and Mackillop, WJ (2014) Peri-operative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer 120:1630-1638. doi:10.1002/cncr.28510. Online.
  22. Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial E, Weir B, Stack E, Park R, O’Brien R, Schultz F, Choueiri T, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia D, Chekaluk Y, Kwiatkowski K, Bochner B, Hahn W, Ligon A, Barletta J, Loda M, Berman DM, Kantoff P, Michor F, and Rosenberg JE (2014) Integrative analysis of 1q23.3 copy number gain in metastatic urothelial carcinoma. Clin Cancer Res, 20:1873-1883. doi:10.1158/1078-0432.CCR-13-0759. Online.
  23. Berman DM and Epstein JI (2014) When is prostate cancer really cancer? Urol Clin North Am, 41:339-346. Online.
  24. Guancial EA, Bellmunt J, Roseberg JE, and Berman DM (2014) The evolving understanding of microRNA in bladder cancer. Urol Oncol, 32:41.e31–41.e40. doi:10.1016/j.urolonc.2013.04.014. Online
  25. Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM, Australian Prostate Cancer BioResource, Taylor RA, and Risbridger GP (2013) A pre-clinical xenograft model identifies castration-tolerant cancer repopulating cells in localized prostate tumors. Sci Transl Med 5:187. doi:10.1126/scitranslmed.3005688. Online
  26. Carvalho LF, Simons BW, Antonarakis ES, Rasheed Z, Douglas N, Villegas D, Matsui W, and Berman DM (2013) Tumorigenic potential of circulating prostate tumor cells. Oncotarget 4:413-421. doi:10.18632/oncotarget.895. online

David M. Berman, MD, PhD, Professor
Department of Pathology and Molecular Medicine
Division of Cancer Biology and Genetics
Cancer Research Institute
Queen's University
Adjunct Faculty, Departments of Pathology, Oncology, and Urology
The Johns Hopkins Medical Institutions

Mailing address:
18 Stuart St., 329 Botterell Hall
Kingston, ON K7L 3N6

Telephones:
Office: 613-533-6000 ext 75218
Mobile: 613-329-1410

bermanlab.org

@Virchow on Twitter